Immuno-persistence Study of A Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years
Phase of Trial: Phase III
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Human papillomavirus 16/18 vaccine recombinant bivalent Xiamen Innovax (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics; Registrational
- 03 Jan 2019 Status changed from active, no longer recruiting to completed.
- 09 Jan 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 04 Jul 2017 New trial record